A Phase 1 interventional study of Zanubrutinib and Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, sponsored by BeiGene. Completed at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.
Sponsored by BeiGene · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse — 19 open to participants now, 23 under way, 1 of them phase 3. zanubrutinib · Lymphoma, Large B-Cell, Diffuse.
Among the 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 6th largest by enrollment, is one of 3 that started in 2020, is one of 3 in phase 1, and was the 3rd registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →19 of the 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 2 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18+
Beijing Tongren Hospital · Sites in China
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 70+
Virginia Commonwealth University · Sites in United States
Ages 18+
By country, each count listing its studies:
zanubrutinib: first FDA approval 2019 (BRUKINSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 39 across the 30 interventional studies. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines: 3 open now, 3 under way, none of them phase 3. Of 7 finished, 6 (86%) have results posted.
Among the 10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines, this one is the 5th largest by enrollment, is one of 2 that started in 2020, is one of 4 in phase 1, and was the 4th registered.
BeOne Medicines’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2017.
3 of the studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06669143Ruijin HospitalZanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission | 2026-11 |
| NCT05873712Aseel AlsouqiZanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | 2026-12-31 |
| NCT07012980Shanghai Zhongshan HospitalGlofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among BeOne Medicines’s 10 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety, tolerability, and efficacy of zanubrutinib in combination with lenalidomide in participants with R/R DLBCL
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received zanubrutinib 160 mg orally twice a day (BID) and lenalidomide 15 mg orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity.
Drug: Zanubrutinib · Drug: Lenalidomide
Participants received zanubrutinib 160 mg orally BID and lenalidomide 20 mg orally QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity.
Drug: Zanubrutinib · Drug: Lenalidomide
Participants received zanubrutinib 160 mg orally BID and lenalidomide 25 mg orally QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity.
Drug: Zanubrutinib · Drug: Lenalidomide
Participants received zanubrutinib 160 mg orally BID and lenalidomide 25 mg orally QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity.
Drug: Zanubrutinib · Drug: Lenalidomide
160 mg administered orally twice daily (BID)
Also known as: BGB-3111, BRUKINSA
Administered orally on Days 1-21 each cycle followed by a mandatory 7-day drug-free interval.
Part 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with lenalidomide). A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death. * Was life threatening. * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical AE by the investigator based on medical judgement (eg, may have jeopardized the patient or may have required medical/surgical intervention to prevent one of the outcomes listed above).
Time frame: From first dose of study drug to 30 days after last dose. Maximum time on treatment in Part 1 was 1260 days.
Part 2: Overall Response Rate (ORR)
ORR is defined as the percentage of participants who achieved a best overall response of partial response (PR) or complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose-positron emission tomography (FDG-PET)). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions.
Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 24 months in Part 2 and 31 months in the RP2D group.
Part 1: Overall Response Rate (ORR)
ORR is defined as the percentage of participants who achieved a best overall response of partial response or complete response based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions.
Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up in Part 1 was 42 months.
Area Under the Plasma Concentration-time Curve From Zero to 8 Hours Postdose (AUCt) of Zanubrutinib After a Single Dose and at Steady State
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Zanubrutinib After a Single Dose and at Steady State
Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of Zanubrutinib After a Single Dose
Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.
Time frame: Cycle 1 Day 1, 0.5, 1, 2, 3, 4, and 8 hours postdose
Maximum Plasma Concentration (Cmax) of Zanubrutinib After a Single Dose and at Steady State
Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Time to Maximum Plasma Concentration (Tmax) of Zanubrutinib After a Single Dose and at Steady State
Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Time to the Last Quantifiable Concentration (Tlast) of Zanubrutinib After a Single Dose and at Steady State
Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Apparent Terminal Elimination Half-life (T1/2) of Zanubrutinib After a Single Dose and at Steady State
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Apparent Volume (CL/F) of Zanubrutinib After a Single Dose and at Steady State
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Apparent Clearance (Vz/F) of Zanubrutinib After a Single Dose and at Steady State
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Accumulation Ratio of AUCt for Zanubrutinib
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL. Accumulation ratio is defined as the ratio of AUCt at steady state (Day 21) to the AUCt after the first dose (Day 1).
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Accumulation Ratio of Cmax for Zanubrutinib
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL. Accumulation ratio is defined as the ratio of Cmax at steady state (Day 21) to the Cmax after the first dose (Day 1).
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Area Under the Plasma Concentration-time Curve From Zero to 8 Hours Postdose (AUCt) of Lenalidomide After a Single Dose and at Steady State
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
AUClast of Lenalidomide After a Single Dose and at Steady State
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
AUCinf of Lenalidomide After a Single Dose
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
Time frame: Cycle 1 Day 1 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Cmax of Lenalidomide After a Single Dose and at Steady State
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Tmax of Lenalidomide After a Single Dose and at Steady State
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Tlast of Lenalidomide After a Single Dose and at Steady State
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
T1/2 of Lenalidomide After a Single Dose and at Steady State
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
CL/F of Lenalidomide After a Single Dose and at Steady State
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Vz/F of Lenalidomide After a Single Dose and at Steady State
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Accumulation Ratio of AUCt for Lenalidomide
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL. Accumulation ratio is defined as the ratio of AUCt at steady state (Day 21) to AUCt after the first dose (Day 1).
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Accumulation Ratio of Cmax for Lenalidomide
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL. Accumulation ratio is defined as the ratio of Cmax at steady state (Day 21) to Cmax after the first dose (Day 1).
Time frame: Cycle 1 Day 1 and Cycle 1 Day 21 at predose and 0.5, 1, 2, 3, 4, and 8 hours postdose
Part 1: Overall Response Rate by Immunohistochemistry Subtypes
ORR is defined as the percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Immunohistochemistry (IHC) was used to identify germinal B-cell-like (GCB) and non-GCB phenotypes.
Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up in Part 1 was 42 months.
Part 1: Overall Response Rate by Gene Expression Profiling (GEP) Subtypes
The percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging. CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR: partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin (COO) assay was used to determine activated B-cell like (ABC) and GCB subtypes.
Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up in Part 1 was 42 months.
Part 2: Overall Response Rate by Immunohistochemistry Subtypes
ORR is defined as the percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification as assessed by the investigator. CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsy (if bone marrow was involved at baseline). PR: partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.
Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 31 months in the RP2D group.
Part 2: Overall Response Rate by Gene Expression Profiling Subtypes
ORR is defined as the percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification assessed by the investigator. CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsy (if bone marrow was involved at baseline). PR: partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Gene expression profiling by HTG EdgeSeq DLBCL COO assay was used to determine ABC and GCB subtypes.
Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 31 months in the RP2D group.
Part 2: Complete Response Rate (CRR)
CRR is defined as the percentage of participants who achieved a best overall response of complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline).
Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 24 months in Part 2 and 31 months in the RP2D group.
Part 2: Complete Response Rate by Immunohistochemistry Subtypes
CRR is defined as the percentage of participants who achieved a best overall response of complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). Immunohistochemistry was used to identify GCB and non-GCB phenotypes.
Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 31 months in the RP2D group.
Part 2: Complete Response Rate by Gene Expression Profiling Subtypes
CRR is defined as the percentage of participants who achieved a best overall response of complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.
Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 31 months in the RP2D group.
Part 2: Duration of Response (DOR)
DOR is defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid assessment. PD: Progressive metabolic disease (increased FDG uptake from Baseline and/or new FDG-avid foci consistent with lymphoma), abnormal node or lesions with longest diameter \> 1.5 cm, an increase of ≥ 50% in the product of the perpendicular diameters, and an increase in the longest diameter of 0.5 cm for lesions ≤ 2 cm or 1.0 cm for lesions \> 2 cm, or any new lesions.
Time frame: From first dose to the end of study; maximum time on follow-up was 24 months in Part 2 and 31 months in the RP2D group.
Part 2: Duration of Response by Immunohistochemistry Subtypes
DOR is defined as the time from the date that the response criteria were first met to the date that progressive disease PD was objectively documented or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid assessment. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.
Time frame: From first dose to the end of study; maximum time on follow-up was 31 months in the RP2D group.
Part 2: Duration of Response by Gene Expression Profiling Subtypes
DOR is defined as the time from the date that the response criteria were first met to the date that progressive disease PD was objectively documented or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid assessment. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.
Time frame: From first dose to the end of study; maximum time on follow-up was 31 months in the RP2D group.
Part 2: Progression-free Survival (PFS)
PFS is defined as the time from the starting date of the combination therapy to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid tumor assessment.
Time frame: From first dose to the end of study; maximum time on follow-up was 24 months in Part 2 and 31 months in the RP2D group.
Part 2: Progression-Free Survival by Immunohistochemistry Subtypes
PFS is defined as the time from the starting date of the combination therapy to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid tumor assessment. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.
Time frame: From first dose to the end of study; maximum time on follow-up was 31 months in the RP2D group.
Part 2: Progression-Free Survival by Gene Expression Profiling Subtypes
PFS is defined as the time from the starting date of the combination therapy to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid tumor assessment. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.
Time frame: From first dose to the end of study; maximum time on follow-up was 31 months in the RP2D group.
Part 2: Time to Response (TTR)
Time to response is defined as time from the starting date of combination therapy to the date the response criteria were first met.
Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 24 months in Part 2 and 31 months in the RP2D group.
Part 2: Time to Response by Immunohistochemistry Subtypes
Time to response is defined as time from the starting date of combination therapy to the date the response criteria were first met. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.
Time frame: Response was assessed every 12 weeks for the first 48 weeks and every 16 weeks for the next 48 weeks and every 24 weeks thereafter; maximum time on follow-up was 31 months in the RP2D group.
Part 2: Time to Response by Gene Expression Profiling Subtypes
Time to response is defined as the time from the starting date of combination therapy to the date objective response criteria were first met. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.
Time frame: From first dose to the end of study; maximum time on follow-up was 31 months in the RP2D group.
Part 2: Number of Participants With Treatment-emergent Adverse Events
An AE is defined as any untoward medical occurrence in a patient temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with lenalidomide). A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death. * Was life threatening. * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical AE by the investigator based on medical judgement (eg, may have jeopardized the patient or may have required medical/surgical intervention to prevent one of the outcomes listed above).
Time frame: From first dose of study drug to 30 days after last dose. Maximum time on treatment in Part 2 was 701 days.
This study was conducted at 10 study centers in China. Participants with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) ineligible for high-dose therapy/stem cell transplant who had received ≥ 1 prior line of systemic therapy were enrolled.
| Milestone | Part 1: Zanubrutinib + Lenalidomide 15 mg | Part 1: Zanubrutinib + Lenalidomide 20 mg | Part 1: Zanubrutinib + Lenalidomide 25 mg | Part 2: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|---|
| Started | 6 | 10 | 11 | 39 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 6 | 10 | 11 | 39 |
| Withdrew: Sponsor ended study | 2 | 4 | 8 | 20 |
| Withdrew: Death | 3 | 5 | 3 | 18 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 1 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with lenalidomide). A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death. * Was life threatening. * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical AE by the investigator based on medical judgement (eg, may have jeopardized the patient or may have required medical/surgical intervention to prevent one of the outcomes listed above).
| Participants | Part 1: Zanubrutinib + Lenalidomide 15 mg | Part 1: Zanubrutinib + Lenalidomide 20 mg | Part 1: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|
| TEAEs | 6 | 10 | 11 |
| SAEs | 0 | 3 | 4 |
ORR is defined as the percentage of participants who achieved a best overall response of partial response (PR) or complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose-positron emission tomography (FDG-PET)). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions.
| percentage of participants | Part 2: Zanubrutinib + Lenalidomide 25 mg | Part 1+2: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|
| Part 2: Overall Response Rate (ORR) | 48.7 (32.4 to 65.2) | 58.0 (43.2 to 71.8) |
ORR is defined as the percentage of participants who achieved a best overall response of partial response or complete response based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions.
| percentage of participants | Part 1: Zanubrutinib + Lenalidomide 15 mg | Part 1: Zanubrutinib + Lenalidomide 20 mg | Part 1: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|
| Part 1: Overall Response Rate (ORR) | 16.7 (0.4 to 64.1) | 30.0 (6.7 to 65.2) | 90.9 (58.7 to 99.8) |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.
| h*ng/mL | Day 1 Zanubrutinib + Lenalidomide | Day 21 Zanubrutinib + Lenalidomide |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Zero to 8 Hours Postdose (AUCt) of Zanubrutinib After a Single Dose and at Steady State | 847.8 ± 80 | 623.9 ± 49 |
Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.
| h*ng/mL | Day 1 Zanubrutinib + Lenalidomide | Day 21 Zanubrutinib + Lenalidomide |
|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Zanubrutinib After a Single Dose and at Steady State | 798.4 ± 94 | 638.4 ± 57 |
Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.
| h*ng/mL | Day 1 Zanubrutinib + Lenalidomide |
|---|---|
| Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of Zanubrutinib After a Single Dose | 943.3 ± 81 |
Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.
| ng/mL | Day 1 Zanubrutinib + Lenalidomide | Day 21 Zanubrutinib + Lenalidomide |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of Zanubrutinib After a Single Dose and at Steady State | 281.2 ± 85 | 208.7 ± 61 |
Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.
| hours | Day 1 Zanubrutinib + Lenalidomide | Day 21 Zanubrutinib + Lenalidomide |
|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Zanubrutinib After a Single Dose and at Steady State | 2.0 (0.9 to 8.0) | 2.5 (0.4 to 8.0) |
Blood samples to characterize the PK profile of zanubrutinib and lenalidomide when given in combination were collected after first dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 1.00 ng/mL.
| hours | Day 1 Zanubrutinib + Lenalidomide | Day 21 Zanubrutinib + Lenalidomide |
|---|---|---|
| Time to the Last Quantifiable Concentration (Tlast) of Zanubrutinib After a Single Dose and at Steady State | 7.9 (7.5 to 8.2) | 7.9 (7.5 to 8.1) |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.
| hours | Day 1 Zanubrutinib + Lenalidomide | Day 21 Zanubrutinib + Lenalidomide |
|---|---|---|
| Apparent Terminal Elimination Half-life (T1/2) of Zanubrutinib After a Single Dose and at Steady State | 1.4 (0.9 to 3.1) | 1.6 (1.1 to 3.0) |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.
| L/h | Day 1 Zanubrutinib + Lenalidomide | Day 21 Zanubrutinib + Lenalidomide |
|---|---|---|
| Apparent Volume (CL/F) of Zanubrutinib After a Single Dose and at Steady State | 165.9 ± 80 | 226.5 ± 46 |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL.
| liters | Day 1 Zanubrutinib + Lenalidomide | Day 21 Zanubrutinib + Lenalidomide |
|---|---|---|
| Apparent Clearance (Vz/F) of Zanubrutinib After a Single Dose and at Steady State | 341.4 ± 69 | 533.8 ± 54 |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL. Accumulation ratio is defined as the ratio of AUCt at steady state (Day 21) to the AUCt after the first dose (Day 1).
| ratio | Zanubrutinib + Lenalidomide |
|---|---|
| Accumulation Ratio of AUCt for Zanubrutinib | 0.7 ± 50 |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation (LLOQ) was 1.00 ng/mL. Accumulation ratio is defined as the ratio of Cmax at steady state (Day 21) to the Cmax after the first dose (Day 1).
| ratio | Zanubrutinib + Lenalidomide |
|---|---|
| Accumulation Ratio of Cmax for Zanubrutinib | 0.8 ± 73 |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
| h*ng/mL | Day 1 Zanubrutinib + Lenalidomide 15 mg | Day 1 Zanubrutinib + Lenalidomide 20 mg | Day 1 Zanubrutinib + Lenalidomide 25 mg | Day 21 Zanubrutinib + Lenalidomide 15 mg | Day 21 Zanubrutinib + Lenalidomide 20 mg | Day 21 Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Zero to 8 Hours Postdose (AUCt) of Lenalidomide After a Single Dose and at Steady State | 843.5 ± 51 | 1092.5 ± 59 | 1177.7 ± 125 | 1091.0 ± 34 | 916.1 ± 39 | 1702.6 ± 29 |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
| h*ng/mL | Day 1 Zanubrutinib + Lenalidomide 15 mg | Day 1 Zanubrutinib + Lenalidomide 20 mg | Day 1 Zanubrutinib + Lenalidomide 25 mg | Day 21 Zanubrutinib + Lenalidomide 15 mg | Day 21 Zanubrutinib + Lenalidomide 20 mg | Day 21 Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|---|---|---|
| AUClast of Lenalidomide After a Single Dose and at Steady State | 641.9 ± 91 | 1072.7 ± 56 | 1187.4 ± 112 | 778.7 ± 69 | 824.6 ± 41 | 1389.7 ± 53 |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
| h*ng/mL | Day 1 Zanubrutinib + Lenalidomide 15 mg | Day 1 Zanubrutinib + Lenalidomide 20 mg | Day 1 Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|
| AUCinf of Lenalidomide After a Single Dose | 933.7 ± 52 | 1443.2 ± 29 | 1752.4 ± 28 |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
| ng/mL | Day 1 Zanubrutinib + Lenalidomide 15 mg | Day 1 Zanubrutinib + Lenalidomide 20 mg | Day 1 Zanubrutinib + Lenalidomide 25 mg | Day 21 Zanubrutinib + Lenalidomide 15 mg | Day 21 Zanubrutinib + Lenalidomide 20 mg | Day 21 Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|---|---|---|
| Cmax of Lenalidomide After a Single Dose and at Steady State | 206.4 ± 118 | 276.5 ± 68 | 332.0 ± 123 | 238.5 ± 132 | 206.6 ± 57 | 372.1 ± 67 |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
| hours | Day 1 Zanubrutinib + Lenalidomide 15 mg | Day 1 Zanubrutinib + Lenalidomide 20 mg | Day 1 Zanubrutinib + Lenalidomide 25 mg | Day 21 Zanubrutinib + Lenalidomide 15 mg | Day 21 Zanubrutinib + Lenalidomide 20 mg | Day 21 Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|---|---|---|
| Tmax of Lenalidomide After a Single Dose and at Steady State | 1.5 (0.5 to 7.6) | 1.5 (0.9 to 4.3) | 2.0 (0.5 to 4.1) | 1.9 (0.5 to 3.8) | 2.1 (0.6 to 4.0) | 1.9 (0.4 to 7.9) |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
| hours | Day 1 Zanubrutinib + Lenalidomide 15 mg | Day 1 Zanubrutinib + Lenalidomide 20 mg | Day 1 Zanubrutinib + Lenalidomide 25 mg | Day 21 Zanubrutinib + Lenalidomide 15 mg | Day 21 Zanubrutinib + Lenalidomide 20 mg | Day 21 Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|---|---|---|
| Tlast of Lenalidomide After a Single Dose and at Steady State | 7.6 (7.6 to 8.0) | 7.9 (7.6 to 8.2) | 8.0 (7.5 to 8.1) | 7.7 (7.5 to 7.9) | 7.7 (7.5 to 8.1) | 8.0 (7.5 to 8.1) |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
| hours | Day 1 Zanubrutinib + Lenalidomide 15 mg | Day 1 Zanubrutinib + Lenalidomide 20 mg | Day 1 Zanubrutinib + Lenalidomide 25 mg | Day 21 Zanubrutinib + Lenalidomide 15 mg | Day 21 Zanubrutinib + Lenalidomide 20 mg | Day 21 Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|---|---|---|
| T1/2 of Lenalidomide After a Single Dose and at Steady State | 2.3 (2.0 to 2.6) | 2.7 (1.7 to 3.9) | 2.5 (1.7 to 7.7) | 2.0 (1.8 to 2.2) | 2.3 (2.0 to 2.9) | 2.4 (1.9 to 3.4) |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
| L/h | Day 1 Zanubrutinib + Lenalidomide 15 mg | Day 1 Zanubrutinib + Lenalidomide 20 mg | Day 1 Zanubrutinib + Lenalidomide 25 mg | Day 21 Zanubrutinib + Lenalidomide 15 mg | Day 21 Zanubrutinib + Lenalidomide 20 mg | Day 21 Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|---|---|---|
| CL/F of Lenalidomide After a Single Dose and at Steady State | 16.1 ± 52 | 16.0 ± 52 | 13.9 ± 41 | 12.8 ± 35 | 17.6 ± 36 | 12.5 ± 31 |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL.
| liters | Day 1 Zanubrutinib + Lenalidomide 15 mg | Day 1 Zanubrutinib + Lenalidomide 20 mg | Day 1 Zanubrutinib + Lenalidomide 25 mg | Day 21 Zanubrutinib + Lenalidomide 15 mg | Day 21 Zanubrutinib + Lenalidomide 20 mg | Day 21 Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|---|---|---|
| Vz/F of Lenalidomide After a Single Dose and at Steady State | 53.6 ± 42 | 62.1 ± 76 | 49.7 ± 49 | 37.3 ± 19 | 57.6 ± 28 | 43.6 ± 20 |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL. Accumulation ratio is defined as the ratio of AUCt at steady state (Day 21) to AUCt after the first dose (Day 1).
| ratio | Zanubrutinib + Lenalidomide 15 mg | Zanubrutinib + Lenalidomide 20 mg | Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|
| Accumulation Ratio of AUCt for Lenalidomide | 1.1 ± 48 | 0.8 ± 106 | 1.0 ± 27 |
Blood samples to characterize the pharmacokinetic (PK) profile of zanubrutinib and lenalidomide when given in combination were collected after a single dose (Cycle 1 Day 1) and at steady state (Cycle 1 Day 21) for participants in Part 1 and for twelve participants from the first stage of enrollment in Part 2. The lower limit of quantitation was 2.00 ng/mL. Accumulation ratio is defined as the ratio of Cmax at steady state (Day 21) to Cmax after the first dose (Day 1).
| ratio | Zanubrutinib + Lenalidomide 15 mg | Zanubrutinib + Lenalidomide 20 mg | Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|
| Accumulation Ratio of Cmax for Lenalidomide | 1.3 ± 51 | 0.8 ± 100 | 0.9 ± 59 |
ORR is defined as the percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Immunohistochemistry (IHC) was used to identify germinal B-cell-like (GCB) and non-GCB phenotypes.
| percentage of participants | GCB Subtype: Zanubrutinib + Lenalidomide 15 mg | Non-GCB Subtype: Zanubrutinib + Lenalidomide 15 mg | GCB Subtype: Zanubrutinib + Lenalidomide 20 mg | Non-GCB Subtype: Zanubrutinib + Lenalidomide 20 mg | GCB Subtype: Zanubrutinib + Lenalidomide 25 mg | Non-GCB Subtype: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|---|---|---|
| Part 1: Overall Response Rate by Immunohistochemistry Subtypes | 33.3 (0.8 to 90.6) | 0.0 (0.0 to 70.8) | 50.0 (6.8 to 93.2) | 16.7 (0.4 to 64.1) | 66.7 (9.4 to 99.2) | 100.0 (63.1 to 100.0) |
The percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging. CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR: partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin (COO) assay was used to determine activated B-cell like (ABC) and GCB subtypes.
| percentage of participants | ABC Subtype: Zanubrutinib + Lenalidomide 15 mg | GCB Subtype: Zanubrutinib + Lenalidomide 15 mg | ABC Subtype: Zanubrutinib + Lenalidomide 20 mg | GCB Subtype: Zanubrutinib + Lenalidomide 20 mg | ABC Subtype: Zanubrutinib + Lenalidomide 25 mg | GCB Subtype: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|---|---|---|
| Part 1: Overall Response Rate by Gene Expression Profiling (GEP) Subtypes | 0.0 (0.0 to 97.5) | 0.0 (0.0 to 97.5) | 12.5 (0.3 to 52.7) | 100.0 (15.8 to 100.0) | 88.9 (51.8 to 99.7) | 100.0 (15.8 to 100.0) |
ORR is defined as the percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification as assessed by the investigator. CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsy (if bone marrow was involved at baseline). PR: partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.
| percentage of participants | GCB Subtype: Zanubrutinib + Lenalidomide 25 mg | Non-GCB Subtype: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|
| Part 2: Overall Response Rate by Immunohistochemistry Subtypes | 50.0 (24.7 to 75.3) | 61.8 (43.6 to 77.8) |
ORR is defined as the percentage of participants who achieved a best overall response of PR or CR based on the Lugano classification assessed by the investigator. CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsy (if bone marrow was involved at baseline). PR: partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions. Gene expression profiling by HTG EdgeSeq DLBCL COO assay was used to determine ABC and GCB subtypes.
| percentage of participants | ABC Subtype: Zanubrutinib + Lenalidomide 25 mg | GCB Subtype: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|
| Part 2: Overall Response Rate by Gene Expression Profiling Subtypes | 68.6 (50.7 to 83.1) | 45.5 (16.7 to 76.6) |
CRR is defined as the percentage of participants who achieved a best overall response of complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline).
| percentage of participants | Part 2: Zanubrutinib + Lenalidomide 25 mg | Part 1+2: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|
| Part 2: Complete Response Rate (CRR) | 33.3 (19.1 to 50.2) | 42.0 (28.2 to 56.8) |
CRR is defined as the percentage of participants who achieved a best overall response of complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). Immunohistochemistry was used to identify GCB and non-GCB phenotypes.
| percentage of participants | GCB Subtype: Zanubrutinib + Lenalidomide 25 mg | Non-GCB Subtype: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|
| Part 2: Complete Response Rate by Immunohistochemistry Subtypes | 50.0 (24.7 to 75.3) | 38.2 (22.2 to 56.4) |
CRR is defined as the percentage of participants who achieved a best overall response of complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using CT and metabolic imaging (FDG-PET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.
| percentage of participants | ABC Subtype: Zanubrutinib + Lenalidomide 25 mg | GCB Subtype: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|
| Part 2: Complete Response Rate by Gene Expression Profiling Subtypes | 45.7 (28.8 to 63.4) | 45.5 (16.7 to 76.6) |
DOR is defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid assessment. PD: Progressive metabolic disease (increased FDG uptake from Baseline and/or new FDG-avid foci consistent with lymphoma), abnormal node or lesions with longest diameter \> 1.5 cm, an increase of ≥ 50% in the product of the perpendicular diameters, and an increase in the longest diameter of 0.5 cm for lesions ≤ 2 cm or 1.0 cm for lesions \> 2 cm, or any new lesions.
| months | Part 2: Zanubrutinib + Lenalidomide 25 mg | Part 1+2: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|
| Part 2: Duration of Response (DOR) | 9.10 (2.79 to NA) | 14.92 (5.45 to NA) |
DOR is defined as the time from the date that the response criteria were first met to the date that progressive disease PD was objectively documented or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid assessment. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.
| months | GCB Subtype: Zanubrutinib + Lenalidomide 25 mg | Non-GCB Subtype: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|
| Part 2: Duration of Response by Immunohistochemistry Subtypes | NA (2.76 to NA) | 11.61 (2.83 to NA) |
DOR is defined as the time from the date that the response criteria were first met to the date that progressive disease PD was objectively documented or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid assessment. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.
| months | ABC Subtype: Zanubrutinib + Lenalidomide 25 mg | GCB Subtype: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|
| Part 2: Duration of Response by Gene Expression Profiling Subtypes | 15.67 (3.02 to NA) | 9.10 (3.02 to NA) |
PFS is defined as the time from the starting date of the combination therapy to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid tumor assessment.
| months | Part 2: Zanubrutinib + Lenalidomide 25 mg | Part 1+2: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|
| Part 2: Progression-free Survival (PFS) | 4.76 (2.73 to 8.94) | 5.52 (2.86 to 11.07) |
PFS is defined as the time from the starting date of the combination therapy to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid tumor assessment. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.
| months | GCB Subtype: Zanubrutinib + Lenalidomide 25 mg | Non-GCB Subtype: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|
| Part 2: Progression-Free Survival by Immunohistochemistry Subtypes | 5.55 (1.61 to NA) | 5.52 (2.86 to 11.04) |
PFS is defined as the time from the starting date of the combination therapy to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Participants who did not have disease progression were censored at their last valid tumor assessment. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.
| months | ABC Subtype: Zanubrutinib + Lenalidomide 25 mg | GCB Subtype: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|
| Part 2: Progression-Free Survival by Gene Expression Profiling Subtypes | 5.55 (4.76 to 18.40) | 5.40 (1.41 to 14.65) |
Time to response is defined as time from the starting date of combination therapy to the date the response criteria were first met.
| months | Part 2: Zanubrutinib + Lenalidomide 25 mg | Part 1+2: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|
| Part 2: Time to Response (TTR) | 2.76 (2.73 to 2.89) | 2.76 (2.73 to 2.83) |
Time to response is defined as time from the starting date of combination therapy to the date the response criteria were first met. Immunohistochemistry was used to identify GCB and non-GCB phenotypes.
| months | GCB Subtype: Zanubrutinib + Lenalidomide 25 mg | Non-GCB Subtype: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|
| Part 2: Time to Response by Immunohistochemistry Subtypes | 2.87 (2.78 to 3.33) | 2.76 (2.73 to 2.79) |
Time to response is defined as the time from the starting date of combination therapy to the date objective response criteria were first met. Gene expression profiling by HTG EdgeSeq DLBCL cell-of-origin assay was used to determine ABC and GCB subtypes.
| months | ABC Subtype: Zanubrutinib + Lenalidomide 25 mg | GCB Subtype: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|
| Part 2: Time to Response by Gene Expression Profiling Subtypes | 2.76 (2.73 to 2.83) | 3.19 (2.79 to 3.48) |
An AE is defined as any untoward medical occurrence in a patient temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with lenalidomide). A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death. * Was life threatening. * Required hospitalization or prolongation of existing hospitalization. * Resulted in disability/incapacity. * Was a congenital anomaly/birth defect. * Was considered a significant medical AE by the investigator based on medical judgement (eg, may have jeopardized the patient or may have required medical/surgical intervention to prevent one of the outcomes listed above).
| Participants | Part 2: Zanubrutinib + Lenalidomide 25 mg |
|---|---|
| TEAEs | 39 |
| SAEs | 14 |
Collected over All-cause mortality: Up to the end of study, maximum time on study was 41.6 months. AEs: From first dose of study drug to 30 days after last dose. Maximum time on treatment was 1260 days.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Zanubrutinib + Lenalidomide 15 mg | 3/6 (50%) | 0/6 (0%) | 6/6 (100%) |
| Part 1: Zanubrutinib + Lenalidomide 20 mg | 5/10 (50%) | 3/10 (30%) | 10/10 (100%) |
| Part 1: Zanubrutinib + Lenalidomide 25 mg | 3/11 (27.3%) | 4/11 (36.4%) | 11/11 (100%) |
| Part 2: Zanubrutinib + Lenalidomide 25 mg | 18/39 (46.2%) | 14/39 (35.9%) | 39/39 (100%) |
| Event | Part 1: Zanubrutinib + Lenalidomide 15 mg | Part 1: Zanubrutinib + Lenalidomide 20 mg | Part 1: Zanubrutinib + Lenalidomide 25 mg | Part 2: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/6 | 2/10 | 2/11 | 4/39 |
| Platelet count decreasedInvestigations | 0/6 | 0/10 | 2/11 | 2/39 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 1/10 | 1/11 | 0/39 |
| Cardiopulmonary failureCardiac disorders | 0/6 | 1/10 | 0/11 | 0/39 |
| COVID-19Infections and infestations | 0/6 | 1/10 | 0/11 | 0/39 |
| Neutrophil count decreasedInvestigations | 0/6 | 1/10 | 1/11 | 2/39 |
| White blood cell count decreasedInvestigations | 0/6 | 1/10 | 0/11 | 0/39 |
| PyrexiaGeneral disorders | 0/6 | 0/10 | 1/11 | 0/39 |
| HypokalaemiaMetabolism and nutrition disorders | 0/6 | 0/10 | 1/11 | 0/39 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/6 | 0/10 | 1/11 | 0/39 |
| Event | Part 1: Zanubrutinib + Lenalidomide 15 mg | Part 1: Zanubrutinib + Lenalidomide 20 mg | Part 1: Zanubrutinib + Lenalidomide 25 mg | Part 2: Zanubrutinib + Lenalidomide 25 mg |
|---|---|---|---|---|
| Neutrophil count decreasedInvestigations | 2/6 | 6/10 | 10/11 | 33/39 |
| White blood cell count decreasedInvestigations | 3/6 | 6/10 | 10/11 | 29/39 |
| AnaemiaBlood and lymphatic system disorders | 2/6 | 4/10 | 8/11 | 21/39 |
| Platelet count decreasedInvestigations | 2/6 | 7/10 | 6/11 | 24/39 |
| Lymphocyte count decreasedInvestigations | 4/6 | 5/10 | 6/11 | 14/39 |
| Blood lactate dehydrogenase increasedInvestigations | 2/6 | 6/10 | 1/11 | 13/39 |
| HypokalaemiaMetabolism and nutrition disorders | 2/6 | 4/10 | 6/11 | 15/39 |
| Weight decreasedInvestigations | 3/6 | 2/10 | 1/11 | 3/39 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/6 | 1/10 | 0/11 | 4/39 |
| Alanine aminotransferase increasedInvestigations | 0/6 | 3/10 | 5/11 | 10/39 |
| Age, Continuous(years) | Part 1: Zanubrutinib + Lenalidomide 15 mg | Part 1: Zanubrutinib + Lenalidomide 20 mg | Part 1: Zanubrutinib + Lenalidomide 25 mg | Part 2: Zanubrutinib + Lenalidomide 25 mg | Total |
|---|---|---|---|---|---|
| Mean | 47.8 ± 15.12 | 54.0 ± 14.83 | 58.8 ± 13.12 | 59.1 ± 11.61 | 57.2 ± 12.86 |
| Sex: Female, Male(Participants) | Part 1: Zanubrutinib + Lenalidomide 15 mg | Part 1: Zanubrutinib + Lenalidomide 20 mg | Part 1: Zanubrutinib + Lenalidomide 25 mg | Part 2: Zanubrutinib + Lenalidomide 25 mg | Total |
|---|---|---|---|---|---|
| Female | 2 | 4 | 6 | 19 | 31 |
| Male | 4 | 6 | 5 | 20 | 35 |
| Race (NIH/OMB)(Participants) | Part 1: Zanubrutinib + Lenalidomide 15 mg | Part 1: Zanubrutinib + Lenalidomide 20 mg | Part 1: Zanubrutinib + Lenalidomide 25 mg | Part 2: Zanubrutinib + Lenalidomide 25 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 6 | 10 | 11 | 39 | 66 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Part 1: Zanubrutinib + Lenalidomide 15 mg | Part 1: Zanubrutinib + Lenalidomide 20 mg | Part 1: Zanubrutinib + Lenalidomide 25 mg | Part 2: Zanubrutinib + Lenalidomide 25 mg | Total |
|---|---|---|---|---|---|
| China | 6 | 10 | 11 | 39 | 66 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beigene.com
Ran from Sep 2020 to primary completion in Mar 2024, 42 months.
Results were first posted in May 2025, 1 year 1 month after primary completion.
Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 71. This study's 42 months is below that.
Counting every sponsor, half of 195 studies reached it within 53 months; a quarter within 35 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zanubrutinib · Lenalidomide
Lymphoma, Large B-Cell, Diffuse →